Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo

Event-free survival of investigational use of libtayo ® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (cscc) from phase 2 trial to be featured in oral presentation
REGN Ratings Summary
REGN Quant Ranking